Comment on 'A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure'

Diabetic Medicine

Volumn 32, Issue 2, 2015, Pages 287-

  Jones, G C ^a   Sainsbury, C A R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; HUMAN; PRACTICE GUIDELINE; ACIDOSIS, LACTIC; BLOOD; DIABETES MELLITUS;

ACIDOSIS, LACTIC; DIABETES MELLITUS; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; METFORMIN;

EID: 84921414922     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12626     Document Type: Article

References (4)

1. Adam WR, O'Brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med 2014; 31: 1032-1038.
2. Bonora E, Cigolini M, Bosello O, Zancanaro C, Capretti L, Zavaroni I et al. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin 1984; 9: 47-51.
3. Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med 1992; 9: 61-65.
4. Baron A, DeFronzo R, Buse J, Kim T, Skare S, Fineman M. Dissociation between metformin plasma exposure and its glucose-lowering effect: a novel gut-mediated mechanism of action. Diabetologia 2013; 56: S67-S67.